1. Home
  2. GSIW vs MBIO Comparison

GSIW vs MBIO Comparison

Compare GSIW & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSIW

Garden Stage Limited

N/A

Current Price

$30.80

Market Cap

33.5M

Sector

N/A

ML Signal

N/A

MBIO

Mustang Bio Inc.

N/A

Current Price

$0.71

Market Cap

5.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSIW
MBIO
Founded
2016
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.5M
5.1M
IPO Year
2022
2023

Fundamental Metrics

Financial Performance
Metric
GSIW
MBIO
Price
$30.80
$0.71
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.1K
44.8K
Earning Date
08-04-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.05
$0.53
52 Week High
$36.90
$7.00

Technical Indicators

Market Signals
Indicator
GSIW
MBIO
Relative Strength Index (RSI) 60.60 52.97
Support Level $0.11 $0.69
Resistance Level $32.67 $0.80
Average True Range (ATR) 2.93 0.07
MACD -0.32 0.01
Stochastic Oscillator 80.00 56.69

Price Performance

Historical Comparison
GSIW
MBIO

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: